Abstract 2093P
Background
The combination treatment of paclitaxel plus ramucirumab [PACL(W)+RAMU] is a widely accepted option for advanced gastric cancer (AGC) as a second-line chemotherapy to prolong survival. The aim of the study is to identify the validity of bioelectrical impedance analysis (BIA) as a prognosticator in patients receiving PACL(W)+RAMU treatment.
Methods
The study population comprised 189 patients who received PACL(W)+RAMU between Oct. 2019 and Nov. 2022. BIA was conducted at baseline of the PACL(W)+RAMU treatment on all patients and whole body PhA was derived. Continuous variables of other body compartment and blood biochemical values (including complete blood count, serum electrolytes and chemistry) were dichotomized according to the best cut-off values determined by the Contal and O’Quigley methods or the normal values. Kaplan-Meier method and the Cox proportional hazard model were constructed to evaluate the prognostic effect the body component.
Results
Median age of the patients was 59. The cut-off value of PhA was determined as 4.6⁰ at 50 kHz. Median overall survival (OS) of the lower PhA group was 38 weeks (95% CI, 32-45) and 52 weeks (95% CI, 39∼65) for higher PhA group (P=0.021). When combining PhA with obesity degree (current weight/target weight x 100), high phA and low obesity degree (< 116%) demonstrated the favorable OS of 54 weeks (95% CI, 40-68), which contrasts to only 14 weeks (95% CI, 10-18) for low PhA and high obesity degree (≥ 116%) group. In multivariate analysis, the PhA combined with obesity degree is an independent prognosticator for OS (hazard ratio [HR], 6.506 for low PhA and high obesity degree, 95% CI, 3.237-13.076, P<0.001) along with neutrophil-to-lymphocyte ratio and extracellular water.
Conclusions
Bioelectrical impedance component and phase angle could be a useful prognosticator for patients with metastatic gastric cancer. Larger sample size and independent set will be needed to further validate the significance of this study in palliative cancer treatment settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2126P - Exercise implementation into a clinic setting with 1.660 cancer patients: Real-world data from eight years oncological exercise therapy in Cologne (OTT)
Presenter: Timo Niels
Session: Poster session 06
2127P - Long-term yoga reduces the side effects of systemic therapies and improves arm symptoms in the breast cancer patients
Presenter: Mayank Jain
Session: Poster session 06
2128P - exerCise discussion with Oncologist duriNg caNcEr ConsultaTion: The CONNECT study
Presenter: Sara Pilotto
Session: Poster session 06
2129P - Feasibility of a virtual exercise program to mitigate decline in physical function for advanced lung cancer patients
Presenter: Ying Wang, Sarah Yeo
Session: Poster session 06